• Datametrex AI Limited (DM) has reported record results for FY 2021
  • Revenue was $49 million compared to $12 million for the same period in 2020, an increase of 296 per cent
  • Net earnings were $9 million, a 282 per cent increase, compared to a $5 million loss in 2020
  • Marshall Gunter, CEO of Datametrex sat down with Shoran Devi to discuss the results
  • Datametrex AI Limited is a technology-focused company
  • Shares of Datametrex AI Limited (DM) opened trading at C$0.16

Datametrex AI Limited (DM) has reported record results for FY 2021.

Revenue was $49 million compared to $12 million for the same period in 2020, an increase of 296 per cent. Net earnings were $9 million, a 282 per cent increase, compared to a $5 million loss in 2020.

Marshall Gunter, CEO of Datametrex sat down with Shoran Devi to discuss the results.

“The 2021 financial results reflect another strong period as the company successfully grows its core AI business and continues to accelerate within the telehealth and health security verticals.”

Financial highlights for the twelve months ended December 31, 2021:

  • Revenue was $49 million compared to $12 million for the same period in 2020, an increase of 296 per cent.
  • Record Adjusted EBITDA of $15M, up 1,838 per cent from FY 2020
  • The company’s cash position improved to $15 million compared to $2 million at the end of 2020.
  • The company added over $2 million in marketable securities
  • The company’s net earnings were $9 million compared to a net loss of $5 million.
  • Gross margin was $21 million compared to $3 million in the previous year, which is an increase of 604 per cent.

Datametrex AI Limited is a technology-focused company with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy.

Shares of Datametrex AI Limited (DM) opened trading at C$0.16.

More From The Market Online

Liberty Defense expands its international customer base

Liberty Defense Holdings (TSXV:SCAN), a provider of artificial intelligence technologies, expands its international customer base.

Theralase advances cancer research after private placement

Theralase Technologies (TSXV:TLT) closes a non-brokered private placement offering of 4.1 million shares for gross proceeds of C$750,200.